Clinical Trial for the Assessment of Delayed Antibiotic Treatment Strategies (NCT01363531) | Clinical Trial Compass
CompletedPhase 4
Clinical Trial for the Assessment of Delayed Antibiotic Treatment Strategies
Spain405 participantsStarted 2009-12
Plain-language summary
The general hypothesis is that delayed antibiotic treatment strategies present similar effectiveness, when compared with non-prescription of antibiotics or the prescription of antibiotics, in the non-complicated acute respiratory tract infections.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
General Inclusion Criteria:
In this study can be enrolled adult patients with non-complicated acute respiratory tract infections, including pharyngitis and/or tonsillitis, rhinosinusitis, acute bronchitis and exacerbations of chronic obstructive pulmonary disease mild to moderate. The doctors include patients with these infections if they have reasonable doubts if the patients should treat with antibiotics
General Exclusion Criteria:
* Patients have participated in the PDA previously.
* Patients are severely affected or patients has been felt severely affected for a week (all time)
* Patients with symptoms and signs suggestive of serious illness or severely affected and/or complications (particularly pneumonia, mastoiditis, peritonsillar abscess, peritonsillar cellulitis, intraorbital or intracranial complications).
* Patients at high risk of serious complications due to prior comorbidity. This includes significant heart disease, lung, kidney, liver or neuromuscular, immunosuppression, cystic fibrosis.
* If the patient is over 65 years with acute cough and two or more of the following criteria or more than 80 years with acute cough and one or more of the following criteria:
* Hospitalization in the previous year
* Diabetes Type I or II
* History of heart failure
* Current use of oral corticosteroids.
What they're measuring
1
Duration and severity of symptoms.
Timeframe: 30 days
Trial details
NCT IDNCT01363531
SponsorFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau